The American Biotechnology Industry Association has endorsed calls from the National Governors' Association and the American Legislative Exchange Council to revamp the US Food and Drug Administration's drug approval policies in order to ensure faster access for patients to new drugs.
The NGA and ALEC proposals also call for more rapid access to diagnostic products and medical devices. The NGA noted that the competiveness of the US market "is dependent on bringing products to the market quickly."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze